Lichen sclerosus unter Einnahme antiandrogenhaltiger Kontrazeptiva bei Frauen zwischen 17 und 40 Jahren

Early onset vulvar Lichen sclerosus in premenopausal women and oral contraceptives

by Melanie Faber
Doctoral thesis
Date of Examination:2014-11-25
Date of issue:2014-11-17
Advisor:Prof. Dr. Günter Emons
Referee:PD Dr. Rotraut Mößner
Referee:Prof. Dr. Martin Oppermann
Persistent Address: http://dx.doi.org/10.53846/goediss-4778

 

 

Files in this item

Name:Diss für SUB ohne Lebenslauf Online 09112014 V7.pdf
Size:261.Kb
Format:PDF

The following license files are associated with this item:

Abstract

English

Objective: For vulvar Lichen sclerosus (LS) immunological factors, genetic predisposition, and decreased 5 alpha-reductase activity have been discussed as aetiological factors. During the last decade an increase of LS in young women has been suspected. Aim of this study was to evaluate data of premenopausal women with early onset LS to find potential risk factors focussing on the use of oral contraceptives. Study design: We retrospectively analyzed the data of 40 premenopausal patients with early onset LS regarding use of oral contraceptives (OCPs), and first occurrence of LS. To compare these data in a case-control study we analyzed a matched control group of 110 healthy women. Results: All our LS patients were using OCPs compared to 73 women (66.4%) in the control group. OCPs with anti-androgenic activity (chlormadinone acetate, cyproterone acetate, dienogest, and drospirenone) were used by 28 (70%) of the LS patients and by 35 (47.9%) of the 73 women using OCPs in the control group. Thus, the odds ratio for early onset LS for women using anti-androgenic OCPs was 2.53 (95% CI: 1.12–5.75). Conclusion: Our data suggest that disturbance of the androgen dependent growth of the vulvar skin by OCPs and especially by OCPs with anti-androgenic properties might trigger the early onset of LS in a subgroup of susceptible young women.
Keywords: Anti-androgenic progestins; Clobetasol propionate; Lichen sclerosus; Oral contraceptives; Progesterone
 
Statistik